GNAS and neoplasm: A recent study using blood and tumour samples from PMP patients (samples used from Clinical Trials.gov; ID: NCT02073500) [30], identified GNAS mutations (R201H and R201C) and suggested the resulting Gsα to be a potential neoantigen.